Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin/Ezetimibe FDC vs Atorvastatin Monotherapy in Hyperlipidemia
NCT06789432Phase 4Withdrawn
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ezetimibe in hyperlipidemia (2 arms). Primary endpoints: Mean change in LDL-C from baseline at 12 weeks and Percentage of patients withdrawn from the study at 12 weeks. Planned start Feb 2025; status: withdrawn.
02
Drugs
ezetimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06789432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789432.